Ampio Pharmaceuticals (AMPE)
(Delayed Data from OTC)
$0.38 USD
+0.06 (18.38%)
Updated Apr 29, 2024 03:26 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Ampio Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 10 | 22 | 21 | 16 | 19 |
Income After Depreciation & Amortization | -10 | -22 | -21 | -16 | -19 |
Non-Operating Income | 1 | 6 | 4 | 0 | 5 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -9 | -16 | -17 | -16 | -14 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -9 | -16 | -17 | -16 | -14 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -9 | -16 | -17 | -16 | -14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -9 | -21 | -19 | -15 | -17 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -10 | -22 | -21 | -16 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.81 | 0.75 | 0.68 | 0.58 | 0.44 |
Diluted EPS Before Non-Recurring Items | -10.66 | -29.40 | -29.99 | -26.99 | -41.98 |
Diluted Net EPS (GAAP) | -10.66 | -29.40 | -29.99 | -26.99 | -41.98 |
Fiscal Year end for Ampio Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.21 | 1.40 | 1.56 | 4.40 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.21 | -1.40 | -1.56 | -4.40 |
Non-Operating Income | NA | 0.16 | 0.17 | 0.19 | 0.42 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.05 | -1.23 | -1.37 | -3.98 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.05 | -1.23 | -1.37 | -3.98 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.05 | -1.23 | -1.37 | -3.98 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.81 | 0.80 | 0.76 | 0.76 |
Diluted EPS Before Non-Recurring Items | NA | -2.48 | -1.53 | -1.80 | -5.20 |
Diluted Net EPS (GAAP) | NA | -2.13 | -1.53 | -1.80 | -5.20 |